- Home
- CVGI vs LPTX Comparison
CVGI vs LPTX Comparison
Compare CVGI & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVGI
- LPTX
- Stock Information
- Founded
- CVGI 2000
- LPTX 2011
- Country
- CVGI United States
- LPTX United States
- Employees
- CVGI N/A
- LPTX N/A
- Industry
- CVGI Auto Parts:O.E.M.
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVGI Consumer Discretionary
- LPTX Health Care
- Exchange
- CVGI Nasdaq
- LPTX Nasdaq
- Market Cap
- CVGI 101.4M
- LPTX 117.1M
- IPO Year
- CVGI 2004
- LPTX N/A
- Fundamental
- Price
- CVGI $2.66
- LPTX $2.95
- Analyst Decision
- CVGI Buy
- LPTX Strong Buy
- Analyst Count
- CVGI 1
- LPTX 5
- Target Price
- CVGI $10.00
- LPTX $10.40
- AVG Volume (30 Days)
- CVGI 263.8K
- LPTX 516.8K
- Earning Date
- CVGI 11-04-2024
- LPTX 11-13-2024
- Dividend Yield
- CVGI N/A
- LPTX N/A
- EPS Growth
- CVGI N/A
- LPTX N/A
- EPS
- CVGI 1.02
- LPTX N/A
- Revenue
- CVGI $912,995,000.00
- LPTX N/A
- Revenue This Year
- CVGI N/A
- LPTX N/A
- Revenue Next Year
- CVGI N/A
- LPTX N/A
- P/E Ratio
- CVGI $2.53
- LPTX N/A
- Revenue Growth
- CVGI 4.14
- LPTX N/A
- 52 Week Low
- CVGI $2.11
- LPTX $1.34
- 52 Week High
- CVGI $7.34
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- CVGI 41.16
- LPTX 44.64
- Support Level
- CVGI $2.46
- LPTX $2.95
- Resistance Level
- CVGI $2.75
- LPTX $3.61
- Average True Range (ATR)
- CVGI 0.22
- LPTX 0.42
- MACD
- CVGI -0.03
- LPTX -0.11
- Stochastic Oscillator
- CVGI 41.23
- LPTX 2.72
About CVGI Commercial Vehicle Group Inc.
Commercial Vehicle Group Inc is a supplier of cab-related products and systems. Its operating segments are Vehicle Solutions, Industrial Automation, Electrical Systems, and Aftermarket and Accessories. Vehicle Solutions segment designs manufacture and sell Commercial vehicle seats and Plastic components. Warehouse Automation segment designs, manufactures, and sells Warehouse automation subsystems including control panels, electro-mechanical assemblies, cable assemblies, and power and communication solutions. Electrical Systems segment designs, manufactures and sells cable and harness assemblies for both high and low voltage applications, control boxes, dashboard assemblies, and design and engineering for these applications. The company makes majority of its revenue from Vehicle Solutions.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .